The inclusion of the first infant just started a clinical phase-2 study of VPM1002, a new Tuberculosis-Vaccine. This newest Tuberculosis-Vaccine in clinical development is expected to reduce the spread of the life-threatening Tuberculosis not only in endemic areas, but also in Europe. VPM1002 was developed jointly by scientists of the Max-Planck Society and the Hannover-based Vaccine Projekt Management GmbH, a spin-off of the Helmholtz Centre for Infection Research.
